bbi – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 6 Results  medlib.snu.ac.kr
  Second Sight İş Ahlakı ...  
Show textShow cached sourceOpen source URL
Faaliyet gösterdiğimiz bir çok ülkenin, ithalat ve ihracat teknolojilerini, kişisel bilgileri ve tıbbi cihazları kontrol eden yasaları mevcuttur. İthalat ve ihracat yasalarının ihlali, bir ülkeye ihraç edilen bir ürünün farklı ithalat ve ihracat kontrollerine konu olan başka bir ülkeye ihracatında meydana gelebilir.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Many countries in which we operate have laws controlling the import and export of technology, personal information, and medical devices. Violations of import and export control laws can occur if items exported to one country are re-exported to another country subject to different import and export controls. Violations can also occur merely by doing business with certain persons or businesses affiliated with, owned by, or controlled by persons designated as “prohibited entities.”
  Second Sight İş Ahlakı ...  
Show textShow cached sourceOpen source URL
İşimizi doğrulukla yaparak, geliştirdiğimiz, ürettiğimiz, test ettiğimiz ve teslim ettiğimiz her bir tıbbi cihazın yürürlükteki hükümet düzenleme standartlarına, bizim kendi sıkı kalite gereksinimlerimize uymasına ve mükemmel hasta bakımına katkıda bulunmasına çabalarız.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
By performing our jobs with integrity, we strive that every single medical device we develop, manufacture, test, and deliver meets applicable government regulatory standards, our own stringent quality requirements, and ultimately contributes to excellent patient care. We all share the responsibility for upholding Second Sight’s standards and ensuring that our regulatory, clinical, and other quality-system policies and procedures are followed. The Quality Policy establishes Second Sight’s commitment to quality. It provides a framework for establishing quality objectives relevant to both the customer needs and the business mission. It currently states: Second Sight is committed to developing and providing safe and effective products and services that comply with all applicable regulatory requirements and consistently meet or exceed the requirements of our customers and the ultimate users, the patients. We train and require all personnel to abide by the quality policy and quality system procedures. The management team and employees are committed to the above policy and to maintaining the effectiveness of the quality management system. Employees should make themselves aware of any revisions.
  Second Sight Yönetim Ku...  
Show textShow cached sourceOpen source URL
'in Başkanlık ve İcra Kurulu Başkanlığını yürütmüştür. Öncesinde ise, halka açık bir tıbbi cihaz şirketi olan Spectranetics Corporation'da Operasyon Direktörlüğü (COO) yapmıştır. McGuire ayrıca, Guidant Corporation'da, 1998 ile 2005 yılları arasında Guidant Latin Amerika Genel Müdürlüğü, ABD Vasküler Müdahale (VI-Vascular Intervention) Pazarlama Direktörlüğü, VI Küresel Pazarlama Direktörlüğü ve Koroner Stent Üretim Yöneticiliği yapmıştır.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Williams is currently the Chairman, President and Chief Executive Officer of Williams International Co., LLC (www.williams-int.com). Prior to his current assignment, Mr. Williams held several key managerial positions within the company including It’s President & Chief Operating Officer, Vice President, Advanced Technology, Director, Program Management and Director, Engineering.  He received a Bachelor of Science degree in mechanical engineering from the University of Utah and holds numerous patents related to gas turbine engines, turbo machinery, and control systems. Mr. Williams also serves on the Board of the General Aviation Manufacturers Association and is a past member of the Young Presidents Organization and Henry Ford Health System’s board of trustees.  He is also an active pilot with multiengine, instrument and seaplane ratings.  Our board believes that Mr. Williams’ executive and managerial experience combined with his leadership skills make him well qualified to serve as one of our directors.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
El Sr. McGuire se incorporó a Second Sight en agosto de 2015 ocupando el cargo de presidente y consejero delegado.  Previamente, trabajó como presidente de Americas Commercial en Volcano Corporation desde el año 2014, y antes de esto, desde 2013 ejerció como vicepresidente senior y gerente general de Gestión de Programas, Sistemas y Procesamiento de Imágenes coronarias. Anteriormente, el Sr. McGuire ostentó el cargo de vicepresidente y gerente general del departamento de Monitorización de Pacientes en Covidien. Antes de esto, fue presidente y consejero delegado de AheroMed, Inc., una empresa de aterectomía periférica respaldada por capital privado y, anteriormente, ejerció como director de operaciones en Spectranetics Corporation, una empresa de dispositivos médicos que cotiza en bolsa. Además, el Sr. McGuire ocupó diversos cargos en Guidant Corporation desde 1998 hasta 2005, incluido el de gerente general de Guidant Latin America, director de Marketing de EE. UU. para Intervención Vascular (IV), director de Marketing Global para IV, y director de Producción para stents coronarios. Antes de 1998, el Sr. McGuire ocupó cargos de los departamentos de Finanzas y Producción en IVAC Medical Systems. Graduado en el Instituto de Tecnología de Georgia, el Sr. McGuire obtuvo su M.B.A. en la Escuela de Negocios Kenan-Flagler perteneciente a la Universidad de Carolina del Norte de Chapel Hill.
  Second Sight Yönetim Ku...  
Show textShow cached sourceOpen source URL
Bay Mendelsohn’un tıbbi cihaz şirketlerindeki kuruculuk tecrübeleri, yönetim kurulu üyelikleri, yöneticilik ve ticari tecrübelerinin yanında finansal tecrübeleri,iş zekası ve yargı becerilerinin yönetim kurulumuza yönetimsel, operasyonel tecrübe ve liderlik beceleri alanında katkı sağladığı düşünülmekte ve kendisini nitelikli bir üye kılmaktadır.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Link has been a member of our Board of Directors since 2003. Mr. Link is a co-founder and managing director of Versant Ventures, a venture capital firm specializing in early-stage investing in healthcare companies, since its inception in 1999. Prior to co-founding Versant Ventures, Mr. Link was a general partner at Brentwood Venture Capital. In 1986 Mr. Link founded Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products. He served as chairman and CEO of Chiron Corporation until it was sold to Bausch and Lomb in 1997. In 1978, Mr. Link founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. From 2002 until 2009, Mr. Link also served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009. Mr. Link was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Mr. Link received his BSc, MSc and Ph.D. from Purdue University. Our board has concluded that Mr. Link’s senior executive history with a focus on medical products as well as his extensive financial and other experience with technology companies in general, including his experience of serving on other boards of directors make him a qualified and valued member of our board.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
M. Pfeffer a rejoint notre Conseil d’administration en mai 2015 et occupe le poste de Président du Comité d’audit.  M. Pfeffer est Vice-président administratif et Directeur financier de MannKind Corporation depuis avril 2008. Depuis janvier 2016, M. Pfeffer est PDG de MannKind Corporation et continue d’occuper le poste de Directeur financier. Auparavant, M. Pfeffer a été Directeur financier et Vice-président principal des services financiers et administratifs de VaxGen, Inc. de mars 2006 à avril 2008, où il était en charge des fonctions financières, fiscales, trésorières, ressources humaines, informatique, achats et installations. Avant d’intégrer VaxGen, M. Pfeffer était Directeur financier de Cell Genesys, Inc. Au cours de ses neuf années passées chez Cell Genesys, M. Pfeffer était Responsable financier avant de devenir Directeur financier en 1998.  Avant cela, M. Pfeffer a occupé une multitude de postes en gestion financière au sein d’autres sociétés, notamment des postes de Contrôleur de gestion, Responsable de l’audit interne et Responsable des rapports financiers. M. Pfeffer a commencé sa carrière chez Price Waterhouse.  M. Pfeffer est diplômé de l’Université de Californie à Berkeley et est également Expert-comptable.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Herr Pfeffer wurde im Mai 2015 Mitglied unseres Board of Directors und ist als Vorsitzender des Prüfungsausschusses tätig.  Im April 2008 begann Herr Pfeffer seine Tätigkeit als Corporate Vice President und Chief Financial Officer (CFO) bei der MannKind Corporation. Seit Januar 2016 ist Herr Pfeffer neben seiner Tätigkeit als CFO auch Chief Executive Officer (CEO) der MannKind Corporation. Zuvor war Herr Pfeffer als CFO und Senior Vice President im Bereich Finanzen und Verwaltung bei VaxGen, Inc. tätig. Im Zeitraum zwischen März 2006 und April 2008 war er für die Bereiche Finanzen, Steuern, Aktien, Personal, IT, Einkauf und Anlagen verantwortlich. Vor seiner Tätigkeit bei VaxGen war Herr Pfeffer CFO bei Cell Genesys, Inc. Bevor er 1998 zum CFO ernannt wurde, war er neun Jahre als Director of Finance bei Cell Genesys tätig.  Davor hatte Herr Pfeffer verschiedene Positionen im Bereich Finanzmanagement in anderen Unternehmen inne, darunter Positionen als Corporate Controller, Manager of Internal Audit und Manager of Financial Reporting. Seine Karriere begann Herr Pfeffer bei Price Waterhouse.  Herr Pfeffer hat einen Abschluss von der University of California, Berkeley, und ist zertifizierter Wirtschaftsprüfer.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
El Sr. Mendelsohn es uno de los fundadores y ha sido director de Second Sight desde la creación de la empresa. El Sr. Mendelsohn se unió a la junta de Advanced Bionics poco después de su fundación en 1993, de la que fue miembro hasta la venta de la empresa en 2004. También fue el fundador y ejerció como director de MRG desde su creación en 1998 hasta su venta en 2001 a Medtronic, Inc. Ha sido miembro de la junta de directores del Instituto Alfred E. Mann de ingeniería biomédica en la Universidad de California del Sur desde su creación en 1998 y forma parte de su comité ejecutivo. En 2007, el Sr. Mendelsohn fundó Nanoprecision Holding Company, Inc., un líder mundial en la manipulación de materiales a escala nanométrica y ha formado parte de su junta directiva desde entonces. También fue fundador y director de Nanoprecision Medical, Inc, una empresa de administración de fármacos que trabaja con nanotecnología, desde su creación en 2011. Es el presidente de la Fundación Maestro, una importante organización musical filantrópica sin ánimo de lucro que realiza ciclos de conciertos de música de cámara de primera categoría y presta instrumentos y arcos de nivel profesional a músicos clásicos jóvenes que deseen desarrollar su carrera profesional en la música, y que él mismo fundó en 1983. El Sr. Mendelsohn está titulado en administración de empresas por la UCLA y J.D. de la Facultad de Derecho de la Universidad Loyola de Los Ángeles. Nuestra junta cree que la experiencia empresarial del Sr. Mendelsohn, incluida su amplia experiencia como fundador, miembro de juntas directivas y director general de empresas de dispositivos médicos, junto con su experiencia financiera, conocimientos empresariales y su buen juicio empresarial proporcionan a nuestra junta una valiosa experiencia práctica y de gestión, además de destrezas de liderazgo que hacen que esté cualificado para ser uno de nuestros directores.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Matthew Pfeffer è entrato nel Consiglio di amministrazione nel mese di maggio 2015 e ricopre il ruolo di Presidente del Comitato di audit.  È stato Vicepresidente corporate e CFO di MannKind Corporation da aprile 2008. Dal mese di gennaio 2016, Pfeffer è CEO di MannKind Corporation pur continuando a rivestire il ruolo di CFO.. In precedenza, Pfeffer è stato CFO e vicepresidente senior della divisione Finance and Administration di VaxGen, Inc. da marzo 2006 ad aprile 2008, ricoprendo responsabilità relative alle funzioni in ambito finanza, imposte, tesoro, risorse umane, IT, acquisti e strutture. Prima di VaxGen, Pfeffer è stato CFO di Cell Genesys, Inc. Durante i nove anni trascorsi in Cell Genesys, Pfeffer è stato Direttore della divisione Finanza prima di essere nominato CFO nel 1998.  Prima di tale ruolo, Pfeffer ha ricoperto diverse altre posizioni di gestione finanziaria in altre aziende, compresi ruoli di Corporate Controller, Manager di Internal Audit e Manager di Financial Reporting. Pfeffer ha cominciato la sua carriera in Price Waterhouse.  Si è laureato presso l'University of California, Berkeley ed è un Dottore commercialista iscritto all'albo.
  Second Sight Yönetim  
Show textShow cached sourceOpen source URL
Steve Okland, 2016 Mart ayında ABD ve Kanada Ticari Başkan Yardımcısı olarak Second Sight'a katılmıştır. Yakın geçmişte, yeni ve orta büyüklükteki tıbbi cihaz şirketleri için ticari yetenek alımı yöneticiliği üzerine uzmanlaşmış olan Okland Group, Inc.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Kukreja is our Vice President, Global Reimbursement & Market Access since October 2016. He joined Second Sight in January 2012 as Director of Market Access, EMEA and successfully expanded reimbursement approvals in some of the key European markets. Between 2007 to 2011, Mr. Kukreja worked as Market Access Consultant where he formulated and executed reimbursement & pricing strategy for several innovative medical devices. As Consultant, he held positions of increasing responsibility at Synergus MedTech Consulting, Sweden (as Associate Director, Project Leader and Project Manager- Global Market Access), Simon-Kucher & Partners, Germany (as Pricing Strategy Consultant) and as a Freelancer. From 2014-2016, he was a member of Eucomed Ophthalmology Group and also led the European MedTech Reimbursement Program at RAPS, Switzerland Chapter. From 2005 to 2007, Mr. Kukreja worked as Sales Representative for Godrej & Boyce, India. Amit holds a Bachelor of Mechanical Engineering from Manipal University, India and an MBA from WHU–Otto Beisheim School of Management, Germany including management modules from Kellogg School of Management, USA, CEIBS, China and IIM Bangalore, India.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Okland a rejoint Second Sight en mars 2016 en tant que vice-président chargé du commerce, pour les États-Unis et le Canada. Il était très récemment président de Sanford Rose Associates – Okland Group, Inc., qui était spécialisé dans l'acquisition de dirigeants commerciaux de talent pour des sociétés de dispositifs médicaux à faible ou moyenne capitalisation. Précédemment, il a été vice-président, marketing et ventes mondiales, de Miramar Labs, Inc., une société de dispositifs médicaux ciblant les troubles dermatologiques et pour laquelle il a dirigé toutes les activités de commercialisation. Avant cela, M. Okland a assuré les fonctions de vice-président, marketing international et ventes aux États-Unis, chez Medivance, Inc. ; il y a dirigé le redressement de toutes les activités commerciales débouchant sur une acquisition de 250 M de dollars par Bard Medical. En tant que vice-président de Spectranetics, Inc., (ventes et marketing États-Unis), il a dirigé toutes les opérations marketing et les ventes aux États-Unis pendant une période où l'entreprise a été citée trois années d'affilée parmi les cent sociétés à croissance les plus rapides de Fortune’s 100. Il a occupé également différents postes commerciaux  avec des responsabilités croissantes pendant 12 ans chez Boston Scientific Corporation et chez Johnson & Johnson Medical, Inc., où il a commencé sa carrière. Il a reçu une licence en sciences (BSc) de l'Université du Wisconsin et une maîtrise en administration des affaires de la Texas Christian University.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Herr Okland trat Second Sight im März 2016 als Geschäfts-Vizepräsident für U.S.A und Kanada bei.  Davor war er Präsident von Sanford Rose Associates – Okland Group, Inc., welche sich auf die Anwerbung von Geschäftsführungstalente für Medizinproduktfirmen im Früh- bis Mittelstadium spezialisiert. Vorgängig diente er als Vizepräsident für Globales Marketing und Verkauf bei Miramar Labs, Inc., einer auf dermatologische medizinische Krankheiten spezialisierte Medizinproduktfirma, wo er alle Vermarktungsaufgaben führte. Davor diente Herr Okland als Vizepräsident für Globales Marketing und Verkauf in den U.S.A. bei Medivance, Inc. und leitete den Turnaround aller Vermarktungstätigkeiten, was zur $ 250 M Übernahme durch Bard Medical führte. Als Vizepräsident für den Vertrieb in den U.S.A. bei Spectranetics, Inc. leitete er alle U.S.A.-Vertriebsgeschäfte während einer Zeit, in welcher die Firma drei Jahre in Folge von Fortune als eine der 100 Fastest Growing Companies geführt wurde. Zudem hielt er während 12 Jahren bei Boston Scientific Corporation und Johnson & Johnson Medical, Inc. verschiedene Stellungen mit wachsender Verantwortung, wo er seine Karriere begann. Er ist Inhaber eines Bachelors of Science von der University of Wisconsin und eines Masters of Business Administration von der Texas Christian University.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
El Sr. Oakland se incorporó a Second Sight en marzo de 2016 como vicepresidente comercial para EE. UU. y Canadá. Más recientemente ha sido presidente de Sanford Rose Associates - Okland Group, Inc., especializados en adquisición de talentos ejecutivos comerciales para empresas de dispositivos médicos en etapas iniciales hasta capitalización mediana. Anteriormente ocupó el puesto de vicepresidente de Marketing y ventas internacionales en Miramar Labs, Inc., una empresa de dispositivos médicos orientados a trastornos dermatológicos, donde tuvo a su cargo todas las actividades de comercialización. Previamente, el Sr. Oakland ocupó el puesto de vicepresidente de Marketing y ventas en EE. UU. en Medivance, Inc., donde dirigió el cambio de rumbo de todas las actividades de comercialización que culminó con la adquisición de Bard Medical por 250 millones de dólares. En Spectranetics, Inc., como vicepresidente de Marketing y ventas en EE. UU., dirigió todas las ventas y operaciones de marketing de EE. UU. durante un periodo en el que la empresa se encontraba entre las 100 compañías de más rápido crecimiento de Fortune. También ha ostentado diversos cargos de ventas de cada vez mayor responsabilidad a lo largo de 12 años en Boston Scientific Corporation y en Johnson & Johnson Medical, Inc., donde inició su carrera. Obtuvo el título de Bachelor of Science en la Universidad de Wisconsin y es Máster en Administración y Dirección de Empresas por la Universidad Cristiana de Texas.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Steve Okland si è unito a Second Sight nel mese di marzo 2016 in qualità di Vicepresidente commerciale di Stati Uniti e Canada.  Precedentemente, ricopriva la carica presidente della Sanford Rose Associates - Okland Group, Inc., specializzata nell'acquisizione di talenti esecutivi a livello commerciale per la fase iniziale di media capitalizzazione delle aziende di dispositivi medici. In precedenza, è stato Vicepresidente del marketing e delle vendite a livello mondiale presso Miramar Labs, Inc., un'azienda di dispositivi medici che si occupa di condizioni mediche dermatologiche, all'interno della quale ha guidato tutte le attività di commercializzazione. Prima ancora, ha ricoperto il ruolo di Vicepresidente del marketing a livello mondiale e delle vendite negli Stati Uniti presso Medivance, Inc. e ha diretto l'inversione di tendenza di tutte le attività di commercializzazione con una conseguente acquisizione pari a 250 milioni di dollari da parte di Bard Medical. Presso Spectranetics, Inc., in qualità di Vicepresidente delle vendite e del marketing negli Stati Uniti, ha diretto tutte le operazioni di vendite e marketing degli Stati Uniti durante un periodo in cui l'azienda è stata nominata tra le 100 Aziende in più rapido sviluppo di Fortune per tre anni consecutivi. Ha inoltre ricoperto varie posizioni di vendita di crescente responsabilità nel corso di 12 anni presso Boston Scientific Corporation e Johnson & Johnson Medical, Inc., dove ha iniziato la propria carriera. Ha conseguito un Bachelor of Science presso l'Università del Wisconsin e un Master in Business Administration presso la Christian University del Texas.
  Second Sight Yönetim  
Show textShow cached sourceOpen source URL
Steve Okland, 2016 Mart ayında ABD ve Kanada Ticari Başkan Yardımcısı olarak Second Sight'a katılmıştır. Yakın geçmişte, yeni ve orta büyüklükteki tıbbi cihaz şirketleri için ticari yetenek alımı yöneticiliği üzerine uzmanlaşmış olan Okland Group, Inc.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Kukreja is our Vice President, Global Reimbursement & Market Access since October 2016. He joined Second Sight in January 2012 as Director of Market Access, EMEA and successfully expanded reimbursement approvals in some of the key European markets. Between 2007 to 2011, Mr. Kukreja worked as Market Access Consultant where he formulated and executed reimbursement & pricing strategy for several innovative medical devices. As Consultant, he held positions of increasing responsibility at Synergus MedTech Consulting, Sweden (as Associate Director, Project Leader and Project Manager- Global Market Access), Simon-Kucher & Partners, Germany (as Pricing Strategy Consultant) and as a Freelancer. From 2014-2016, he was a member of Eucomed Ophthalmology Group and also led the European MedTech Reimbursement Program at RAPS, Switzerland Chapter. From 2005 to 2007, Mr. Kukreja worked as Sales Representative for Godrej & Boyce, India. Amit holds a Bachelor of Mechanical Engineering from Manipal University, India and an MBA from WHU–Otto Beisheim School of Management, Germany including management modules from Kellogg School of Management, USA, CEIBS, China and IIM Bangalore, India.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Mr. Okland a rejoint Second Sight en mars 2016 en tant que vice-président chargé du commerce, pour les États-Unis et le Canada. Il était très récemment président de Sanford Rose Associates – Okland Group, Inc., qui était spécialisé dans l'acquisition de dirigeants commerciaux de talent pour des sociétés de dispositifs médicaux à faible ou moyenne capitalisation. Précédemment, il a été vice-président, marketing et ventes mondiales, de Miramar Labs, Inc., une société de dispositifs médicaux ciblant les troubles dermatologiques et pour laquelle il a dirigé toutes les activités de commercialisation. Avant cela, M. Okland a assuré les fonctions de vice-président, marketing international et ventes aux États-Unis, chez Medivance, Inc. ; il y a dirigé le redressement de toutes les activités commerciales débouchant sur une acquisition de 250 M de dollars par Bard Medical. En tant que vice-président de Spectranetics, Inc., (ventes et marketing États-Unis), il a dirigé toutes les opérations marketing et les ventes aux États-Unis pendant une période où l'entreprise a été citée trois années d'affilée parmi les cent sociétés à croissance les plus rapides de Fortune’s 100. Il a occupé également différents postes commerciaux  avec des responsabilités croissantes pendant 12 ans chez Boston Scientific Corporation et chez Johnson & Johnson Medical, Inc., où il a commencé sa carrière. Il a reçu une licence en sciences (BSc) de l'Université du Wisconsin et une maîtrise en administration des affaires de la Texas Christian University.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Herr Okland trat Second Sight im März 2016 als Geschäfts-Vizepräsident für U.S.A und Kanada bei.  Davor war er Präsident von Sanford Rose Associates – Okland Group, Inc., welche sich auf die Anwerbung von Geschäftsführungstalente für Medizinproduktfirmen im Früh- bis Mittelstadium spezialisiert. Vorgängig diente er als Vizepräsident für Globales Marketing und Verkauf bei Miramar Labs, Inc., einer auf dermatologische medizinische Krankheiten spezialisierte Medizinproduktfirma, wo er alle Vermarktungsaufgaben führte. Davor diente Herr Okland als Vizepräsident für Globales Marketing und Verkauf in den U.S.A. bei Medivance, Inc. und leitete den Turnaround aller Vermarktungstätigkeiten, was zur $ 250 M Übernahme durch Bard Medical führte. Als Vizepräsident für den Vertrieb in den U.S.A. bei Spectranetics, Inc. leitete er alle U.S.A.-Vertriebsgeschäfte während einer Zeit, in welcher die Firma drei Jahre in Folge von Fortune als eine der 100 Fastest Growing Companies geführt wurde. Zudem hielt er während 12 Jahren bei Boston Scientific Corporation und Johnson & Johnson Medical, Inc. verschiedene Stellungen mit wachsender Verantwortung, wo er seine Karriere begann. Er ist Inhaber eines Bachelors of Science von der University of Wisconsin und eines Masters of Business Administration von der Texas Christian University.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
El Sr. Oakland se incorporó a Second Sight en marzo de 2016 como vicepresidente comercial para EE. UU. y Canadá. Más recientemente ha sido presidente de Sanford Rose Associates - Okland Group, Inc., especializados en adquisición de talentos ejecutivos comerciales para empresas de dispositivos médicos en etapas iniciales hasta capitalización mediana. Anteriormente ocupó el puesto de vicepresidente de Marketing y ventas internacionales en Miramar Labs, Inc., una empresa de dispositivos médicos orientados a trastornos dermatológicos, donde tuvo a su cargo todas las actividades de comercialización. Previamente, el Sr. Oakland ocupó el puesto de vicepresidente de Marketing y ventas en EE. UU. en Medivance, Inc., donde dirigió el cambio de rumbo de todas las actividades de comercialización que culminó con la adquisición de Bard Medical por 250 millones de dólares. En Spectranetics, Inc., como vicepresidente de Marketing y ventas en EE. UU., dirigió todas las ventas y operaciones de marketing de EE. UU. durante un periodo en el que la empresa se encontraba entre las 100 compañías de más rápido crecimiento de Fortune. También ha ostentado diversos cargos de ventas de cada vez mayor responsabilidad a lo largo de 12 años en Boston Scientific Corporation y en Johnson & Johnson Medical, Inc., donde inició su carrera. Obtuvo el título de Bachelor of Science en la Universidad de Wisconsin y es Máster en Administración y Dirección de Empresas por la Universidad Cristiana de Texas.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine secondsight.com as primary domain
Steve Okland si è unito a Second Sight nel mese di marzo 2016 in qualità di Vicepresidente commerciale di Stati Uniti e Canada.  Precedentemente, ricopriva la carica presidente della Sanford Rose Associates - Okland Group, Inc., specializzata nell'acquisizione di talenti esecutivi a livello commerciale per la fase iniziale di media capitalizzazione delle aziende di dispositivi medici. In precedenza, è stato Vicepresidente del marketing e delle vendite a livello mondiale presso Miramar Labs, Inc., un'azienda di dispositivi medici che si occupa di condizioni mediche dermatologiche, all'interno della quale ha guidato tutte le attività di commercializzazione. Prima ancora, ha ricoperto il ruolo di Vicepresidente del marketing a livello mondiale e delle vendite negli Stati Uniti presso Medivance, Inc. e ha diretto l'inversione di tendenza di tutte le attività di commercializzazione con una conseguente acquisizione pari a 250 milioni di dollari da parte di Bard Medical. Presso Spectranetics, Inc., in qualità di Vicepresidente delle vendite e del marketing negli Stati Uniti, ha diretto tutte le operazioni di vendite e marketing degli Stati Uniti durante un periodo in cui l'azienda è stata nominata tra le 100 Aziende in più rapido sviluppo di Fortune per tre anni consecutivi. Ha inoltre ricoperto varie posizioni di vendita di crescente responsabilità nel corso di 12 anni presso Boston Scientific Corporation e Johnson & Johnson Medical, Inc., dove ha iniziato la propria carriera. Ha conseguito un Bachelor of Science presso l'Università del Wisconsin e un Master in Business Administration presso la Christian University del Texas.